Advancing Biotechnology Research
Antitope is pioneering a new generation of immunogenicity testing, antibody humanization and protein engineering technologies.
Our mission is to apply these technologies to create improved non-immunogenic biologics. Formed in 2004, Antitope provides proprietary technologies as a comprehensive service for the preclinical prediction of clinical immunogenicity, and for the generation of humanized antibodies, therapeutic proteins and recombinant vaccines. To date, we have entered into multiple agreements with pharmaceutical and biotechnology companies worldwide to apply our technologies for the development of improved biologics.
News & Press
25.08.2010
Antitope Announces Research Collaboration with Ablynx
25 August 2010 - Antitope Ltd. of Cambridge UK (“Antitope”) today announced a research collaboration with Ablynx NV of Ghent, Belgium ("Ablynx")...
Antitope Announces Research Collaboration with Ablynx
25 August 2010 - Antitope Ltd. of Cambridge UK (“Antitope”) today announced a research collaboration with Ablynx NV of Ghent, Belgium ("Ablynx")...
19.07.2010
Antitope Announces EpiScreen Collaboration with PIKAMAB
19 July 2010 - Antitope Ltd. today announced a research collaboration with PIKAMAB, Inc. ("PIKAMAB") whereby Antitope will apply its proprietary...
Antitope Announces EpiScreen Collaboration with PIKAMAB
19 July 2010 - Antitope Ltd. today announced a research collaboration with PIKAMAB, Inc. ("PIKAMAB") whereby Antitope will apply its proprietary...
